Commercial utilities and future perspective of nanomedicines

Malviya, Rishabha; Fuloria, Shivkanya; Verma, Swati; Subramaniyan, Vetriselvan; Sathasivam, Kathiresan V.; Kumarasamy, Vinoth; Kumar, Darnal Hari; Vellasamy, Shalini; Meenakshi, Dhanalekshmi Unnikrishnan; Yadav, Shikha; Sharma, Akanksha; Fuloria, Neeraj Kumar

doi:10.7717/peerj.12392

Cited by 16 publications

(8 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a state-of-the-art therapeutic strategy, nanotechnology offers an array of possibilities by enabling interconnected platforms to solve unmet needs and problems ( Malviya et al, 2021 ). Nanomedicines’ nanoscale size (1–100 nm) and large surface area make them ideal platforms for accessing biological targets and interacting with cells and tissues precisely ( Sahoo et al, 2007 ).…”

Section: Therapeutics For Nddsmentioning

confidence: 99%

See 1 more Smart Citation

Role of microglia autophagy and mitophagy in age-related neurodegenerative diseases

Lin

Xie

et al. 2023

Front. Aging Neurosci.

View full text Add to dashboard Cite

Microglia, characterized by responding to damage, regulating the secretion of soluble inflammatory mediators, and engulfing specific segments in the central nervous system (CNS), function as key immune cells in the CNS. Emerging evidence suggests that microglia coordinate the inflammatory responses in CNS system and play a pivotal role in the pathogenesis of age-related neurodegenerative diseases (NDDs). Remarkably, microglia autophagy participates in the regulation of subcellular substances, which includes the degradation of misfolded proteins and other harmful constituents produced by neurons. Therefore, microglia autophagy regulates neuronal homeostasis maintenance and process of neuroinflammation. In this review, we aimed at highlighting the pivotal role of microglia autophagy in the pathogenesis of age-related NDDs. Besides the mechanistic process and the co-interaction between microglia autophagy and different kinds of NDDs, we also emphasized potential therapeutic agents and approaches that could be utilized at the onset and progression of these diseases through modulating microglia autophagy, including promising nanomedicines. Our review provides a valuable reference for subsequent studies focusing on treatments of neurodegenerative disorders. The exploration of microglia autophagy and the development of nanomedicines greatly enhances current understanding of NDDs.

show abstract

Section: Therapeutics For Nddsmentioning

confidence: 99%

“…MCPZFS NPs have the ability to recruit Aβ into microglia and enhance Aβ phagocytosis, which may potentially contribute to non-covalent interaction between PCB and Aβ ( Figure 4A ). There is a possibility that PCB-based nanomaterials could be used as zwitterionic drugs to treat AD ( Malviya et al, 2021 ).…”

Section: Therapeutics For Nddsmentioning

confidence: 99%

Role of microglia autophagy and mitophagy in age-related neurodegenerative diseases

Lin

Xie

et al. 2023

Front. Aging Neurosci.

View full text Add to dashboard Cite

show abstract

“…By 2015, a total of 13 nanomedicines had been approved by the US FDA for the treatment of different diseases (Malviya et al 2021 ). However, of recent, there has been a rocketing surge in the number of nanomedicine clinical trials.…”

Section: Clinical Trials Of Nanomedicine-based Formulationsmentioning

confidence: 99%

Nanomedicine-based commercial formulations: current developments and future prospects

Thapa

Kim

2022

J. Pharm. Investig.

View full text Add to dashboard Cite

Background In recent decades, there has been a considerable increase in the number of nanomedicine-based formulations, and their advantages, including controlled/targeted drug delivery with increased efficacy and reduced toxicity, make them ideal candidates for therapeutic delivery in the treatment of complex and difficult-to-treat diseases, such as cancer. Areas covered This review focuses on nanomedicine-based formulation development, approved and marketed nanomedicines, and the challenges faced in nanomedicine development as well as their future prospects. Expert opinion To date, the Food and Drug Administration and the European Medicines Agency have approved several nanomedicines, which are now commercially available. However, several critical challenges, including reproducibility, proper characterization, and biological evaluation, e.g., via assays, are still associated with their use. Therefore, rigorous studies alongside stringent guidelines for effective and safe nanomedicine development and use are still warranted. In this study, we provide an overview of currently available nanomedicine-based formulations. Thus, the findings here reported may serve as a basis for further studies regarding the use of these formulations for therapeutic purposes in near future.

show abstract

“…Nanotechnology has emerged as a critical technique for overcoming fundamental (bio)pharmaceutical issues like decreased physicochemical stability, low aqueous solubility, and inadequate bioavailability [1,2]. Nano-drug delivery systems can specifically target the cells and tissues, thereby augmenting the total drug payload at the intended location of the body and limiting the adverse effect by reducing the direct systemic exposure [3,4].…”

Section: Introductionmentioning

confidence: 99%

Nanomedicines in the pediatric therapy: Tribulation and road ahead

chen

Jiang

2022

Arch Med Sci

View full text Add to dashboard Cite

Nanotechnology has emerged as a critical technique for overcoming medicines' primary (bio)pharmaceutical disadvantages and enabling active or passive targeting of certain cells and organs. Majority of pediatric treatments are based on adult clinical experience. However, a solid concept that medication pharmacokinetics and therapeutic outcomes differ in children and adults. The interaction of certain medicines with their target receptors, varies with the maturity of various organs and systems. Usual observations are seen for toxic-side and adverse effects. Implementing innovative technologies in the pediatric population (e.g., nanotechnology) becomes exceedingly difficult in this environment. The article aims to deliver an overview of numerous initiatives to utilise nanotechnology to cure illnesses in children. We first discuss basic in vitro research through preclinical and clinical trials aimed at treating children infectious illnesses and paediatric solid tumours using nanotechnology, despite little existing literature on this subject. Finally, future perspectives of nanomedicine for pediatric population are elaborated.

show abstract

Commercial utilities and future perspective of nanomedicines

Cited by 16 publications

References 79 publications

Role of microglia autophagy and mitophagy in age-related neurodegenerative diseases

Role of microglia autophagy and mitophagy in age-related neurodegenerative diseases

Nanomedicine-based commercial formulations: current developments and future prospects

Nanomedicines in the pediatric therapy: Tribulation and road ahead

Contact Info

Product

Resources

About